Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Akcea Therapeutics, Inc.    AKCA

AKCEA THERAPEUTICS, INC.

(AKCA)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Akcea, Ionis Close Licensing Agreement with Pfizer on New Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/19/2019 | 05:38pm EST

By Stephen Nakrosis

Akcea Therapeutics and Ionis Pharmaceuticals said Tuesday they closed an exclusive licensing deal with Pfizer for AKCEA-ANGPTL3-L(Rx).

The companies said AKCEA-ANGPTL3-L(Rx) is an investigational therapy discovered by Ionis which is being developed for the treatment of certain cardiovascular and metabolic diseases.

Under the terms of the deal, Pfizer will receive an exclusive license to develop, make and commercialize AKCEA-ANGPTL3-L(Rx) worldwide.

Akcea and Ionis will receive $250 million upfront license fee, to be split equally. Akcea, which is a majority-owned affiliate of Ionis, will settle its $125 million obligation to Ionis in Akcea common stock, the companies said.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
AKCEA THERAPEUTICS, INC. 0.17% 17.64 Delayed Quote.-41.47%
IONIS PHARMACEUTICALS, INC. 0.12% 64.61 Delayed Quote.19.37%
PFIZER 0.68% 38.29 Delayed Quote.-12.28%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AKCEA THERAPEUTICS, INC.
12/04AKCEA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Financial ..
AQ
12/04Akcea Announces Appointment of New Chief Operating Officer
GL
11/25Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Tria..
GL
11/19Akcea, Ionis Close Licensing Agreement with Pfizer on New Drug
DJ
11/19Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for ..
GL
11/13Akcea Therapeutics to Present at Upcoming Investor Conferences
GL
11/06AKCEA THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
11/05AKCEA THERAPEUTICS : 3Q Earnings Snapshot
AQ
11/05AKCEA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financ..
AQ
11/05Akcea Reports Financial Results and Highlights for Third Quarter 2019
GL
More news
Financials (USD)
Sales 2019 433 M
EBIT 2019 35,9 M
Net income 2019 40,1 M
Finance 2019 336 M
Yield 2019 -
P/E ratio 2019 252x
P/E ratio 2020 -13,4x
EV / Sales2019 3,05x
EV / Sales2020 5,84x
Capitalization 1 656 M
Chart AKCEA THERAPEUTICS, INC.
Duration : Period :
Akcea Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AKCEA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 32,75  $
Last Close Price 17,64  $
Spread / Highest target 155%
Spread / Average Target 85,7%
Spread / Lowest Target 41,7%
EPS Revisions
Managers
NameTitle
Damien McDevitt Chief Executive Officer & Director
Christopher F. O. Gabrieli Chairman
Alex G. Howarth Chief Operating Officer
Michael F. MacLean CFO & Principal Accounting Officer
Louis St. Laurence O'Dea Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
AKCEA THERAPEUTICS, INC.-41.47%1 656
JOHNSON & JOHNSON8.78%369 462
ROCHE HOLDING AG25.45%263 079
MERCK AND COMPANY16.28%226 211
PFIZER-12.28%211 902
NOVARTIS22.87%208 547